Immune deposits/complexes are detected in a multitude of tissues in autoimmune disorders, but no organ has attracted as much attention as the kidney. Several kidney diseases are characterised by the presence of specific configurations of such deposits, and many of them are under a ‘shared care’ between rheumatologists and nephrologists. This review focuses on five different diseases commonly encountered in rheumatological and nephrological practice, namely IgA vasculitis, lupus nephritis, cryoglobulinaemia, anti-glomerular basement membrane disease and anti-neutrophil cytoplasm-antibody glomerulonephritis. They differ in disease aetiopathogenesis, but also the potential speed of kidney function decline, the responsiveness to immunosuppression/immunomodulation and the deposition of immune deposits/complexes. To date, it remains unclear if deposits are causing a specific disease or aim to abrogate inflammatory cascades responsible for tissue damage, such as neutrophil extracellular traps or the complement system. In principle, immunosuppressive therapies have not been developed to tackle immune deposits/complexes, and repeated kidney biopsy studies found persistence of deposits despite reduction of active inflammation, again highlighting the uncertainty about their involvement in tissue damage. In these studies, a progression of active lesions to chronic changes such as glomerulosclerosis was frequently reported. Novel therapeutic approaches aim to mitigate these changes more efficiently and rapidly. Several new agents, such as avacopan, an oral C5aR1 inhibitor, or imlifidase, that dissolves IgG within minutes, are more specifically reducing inflammatory cascades in the kidney and repeat tissue sampling might help to understand their impact on immune cell deposition and finally kidney function recovery and potential impact of immune complexes/deposits.
- immune complex diseases
- lupus nephritis
- systemic vasculitis
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
The term immune-complex glomerulonephritis (ICGN) is used in connection with specific disease entities and denotes a pattern of disease in which an immune-mediated process resulting in glomerular deposits has led to kidney injury. The huge complexity behind the term could easily be underestimated: there are numerous kidney diseases that are characterised by the presence of deposits; but not all deposits are immune deposits, and not all immune deposits are immune complexes.1 However, regardless of the nature of the deposits, they are considered to initiate and perpetuate an inflammatory response and further abrogate tolerance mechanisms of both B and T cells,2 critical in the pathogenesis of autoimmunity.
Renal pathologists mostly use combinations of findings by immunofluorescence (IF) staining and electron microscopy (EM) to determine the nature and location of all kinds of deposits in a kidney biopsy. This enables the distinction between an enormous variety of deposits sharing characteristics by either one technique but are different by mutual exclusion. For example, in C3 glomerulonephritis, C3 is the dominant staining by IF, but the variant dense deposit disease can only be recognised by EM.3
For this review, we have chosen to focus on five kidney diseases that are commonly encountered by the rheumatologists: IgA vasculitis (IgAV), lupus nephritis (LN), cryoglobulinaemia, anti-glomerular basement membrane (GBM) disease and anti-neutrophil cytoplasm-antibody glomerulonephritis (ANCA-GN). For the latter, its denotation as an ICGN may be questioned as indicated already by its other name ‘pauci-immune glomerulonephritis’. However, recent evidence highlights the importance of deposition of especially complement fragments in kidney biopsy specimens of patients with ANCA-GN. We also include it in this review because of its relevance for the rheumatologist. Most importantly, whereas pathogenesis of the five diseases that are the focus of our review may differ, they share the important clinical threat of turning into chronic kidney disease (CKD) and frequently require a shared care by rheumatologists and nephrologists.
The discussed diseases not only differ among each other in terms of organ manifestations (table 1), also within their own spectrum marked differences are apparent, for instance in their clinical presentation, treatment response and outcomes. Kidney disease clinically presents as nephritic syndrome in IgAV, cryoglobulinaemia, anti-GBM disease and ANCA-GN, while patients with LN present with different degrees of nephrosis (although often as non-nephrotic proteinuria, and might also present with a degree of haematuria and thus nephritis). The differences in symptoms between nephritic syndrome and nephrosis are highlighted in table 2. Assessment of kidney function (serum creatinine, estimated glomerular filtration rate (eGFR)) and urinalysis, both at diagnosis and follow-up visits, is needed to detect overt kidney involvement in cases with a mainly extra-renal initial manifestation. Early referral to nephrology to verify kidney involvement and establish a therapeutic concept directed to limit the extent of kidney damage (ie, sclerosis) is needed as part of a shared care between specialties.
Presenting symptoms together with pathogenetic insights of the five diseases which we focus on in this review are summarised below.
IgAV is more common in childhood and presents less frequently with kidney involvement in comparison to adulthood.4 The presence of a skin rash is a prerequisite of the disease, and often self-limiting.5 Renal involvement is considered an entity with IgA-dominant glomerulonephritis, very much similar to the more frequently occurring IgA nephropathy (IgAN). In the skin, IgA deposits typically occur in foci with small vessel vasculitis. In particular in children, the presenting symptoms of skin involvement on the legs are most commonly known as Henoch-Schönlein purpura, but there are many manifestations for which the term IgA vasculitis is used that are less well defined. Clinical symptoms indicative of renal involvement may not always lead to performance of a renal biopsy—but if they do, the findings in the biopsy may be similar in various aspects to IgAN: both entities share the presence of IgA1 subclass in circulating immune complexes resulting in a pattern of IgA deposition in mesangial areas (figure 1A), accompanied by characteristic mesangial hypercellularity by light microscopy (figure 2A).6 In combination with IgA1 deposition, complement C3 is frequently detected in glomeruli, reflecting the involvement of the lectin and alternative pathway in IgAV pathogenesis.5 It is generally considered that endocapillary hypercellularity and crescent formation are more commo than its counterpart IgAN, perhaps in relation to the occurrence of deposits along capillary loops in addition to those in mesangial areas. In IgAN, extracapillary proliferation is regarded as an independent variable associated with a faster decline of kidney function.7
LN in systemic lupus erythematosus
LN will ultimately be present in at least 50% of systemic lupus erythematosus (SLE) cases, and proteinuria, in some subjects presenting with severe nephrosis (including respiratory compromise, pitting oedema, severe hypertension), is the presenting feature in most patients. In the absence of other pathologies, LN classes III, IV and V require immunosuppressive therapy.8
LN is characterised by the most extensive pattern of deposition known in renal histology where all a so-called full house staining pattern (referring to simultaneous positivity for IgA, IgG, IgM, C3, C1q and light chains, depicted in figure 3A–G) in glomeruli present in various deposition patterns (mesangial (figure 2B), endocapillary (figure 2D) and membranous) are encountered, which together, form the basis for the distinction in LN classes, and moreover, they are closely associated with clinical symptoms (figure 4).9 A multitude of antibodies and immune complexes are involved in LN, and although the inflammatory process may be destroying the glomerular structure, the deposits that have triggered this process in the first place, remain visible in the midst of the glomerular damage. It is perhaps also because LN involves so many different autoantibodies and immune complexes acting together that a huge variety of glomerular lesions are encountered.10 11 Some of these have a very close relation to light microscopic lesions, for instance, wire loops (figure 2F) and pseudothrombi that are almost synonymous with the subendothelial deposits themselves. A recent histopathologic subclassification indicated that the majority of global class IV LN present with a membranoproliferative glomerulonephritis (MPGN)-like pattern reflected by presence of global endocapillary hypercellularity, wire loops and double contours, while class III LN is characterised by segmental endocapillary hypercellularity and thus resembles a vasculitis-like pattern.12 Membranous LN (class V, IF pattern shown in figure 1B) is characterised by subepithelial deposits which involve more than half of capillary loops of more than half of glomeruli with mesangial deposits.13
Disease antigens have been identified in class V LN. Exostosin 1 and exostosin 2 are present in around a third of the patients, and these patients present at a younger age and with less severe chronic damage on kidney biopsy.14 Another identified antigen is neural cell adhesion molecule 1, which is present in around 6.6% of cases with class V LN.15
Initial presentation of cryoglobulinaemic disease differs among patients, and spans from relatively mild cases to life-threatening disease with a rapid decline in kidney function. Organ manifestations often result in significant morbidity and cumulative organ impairment.16 Of the glomerular diseases that are discussed in this review, cryoglobulinaemic GN17 is the only one for which EM is essential to the diagnosis. From a light microscopic perspective, cryoglobulinaemic GN shares the most similarities with LN class IV. Lupus-like lesions such as pseudothrombi, and lesions similar to wire loops (figure 2E) are revealed by EM to consist of cryoglobulins, which show a microtubular substructure, rather than the more regular deposits that are found in LN. Endocapillary and mesangial cell proliferation, thickening of the GBM and subendothelial deposits resembling a MPGN-pattern can be indicative of cryoglobulinaemic GN. A third of the biopsies also reveal vasculitis of small-sized and medium-sized arteries with fibrinoid necrosis.18 From a clinical perspective, cryoglobulins have been subcategorised in types 1, 2 and 3, but all of these may contain IgG and/or IgM and lead to similar findings by EM. Types 1–3 are almost indistinguishable according to the findings in the biopsy, although characterisation by IF (figure 1C) may be helpful as type 1 characteristically should have a light chain restriction, type 2 an IgM kappa predominance, whereas type 3 has mixed immunoglobulins.
Anti-GBM disease presents with kidney disease in almost all patients, and is characterised by a rapid deterioration of kidney function. Many patients present with dialysis-dependency, and the presence of oliguria and especially anuria portends a risk factor for remaining on dialysis even after immediate treatment initiation.
Presence of anti-GBM antibodies can be detected in blood of most patients, or by direct IF on a biopsy specimen. The typical finding on direct IF is a linear IgG staining along the GBM, which is often accompanied by some degree of complement deposition.19 This finding by IF (as depicted in figure 1D) strinkingly reveals the pathogenetic mechanism of anti-GBM disease because it represents binding of autoantibodies to the well characterised autoantigen expressed in the basement membrane.20 By light microscopy, anti-GBM disease is characterised by a crescentic glomerulonephritis which develops after destruction of the GBM due to the inflammatory response that evolves from IgG binding. Because this is an acute process by which the entire GBM of all glomeruli is being targeted in a relatively short time, typically, cellular crescents are present in the majority of glomeruli in the renal biopsy. It is generally acknowledged that if 100% of glomeruli in a renal biopsy have crescents, outcome is poor. This rule of thumb is based on a series of 71 patients: in this study, no patient who required haemodialysis and had 100% crescents on kidney biopsy recovered renal function.21 In a recent study of 123 patients, it was shown that there is some variability in the histological patterns of anti-GBM disease. For instance, younger patients in particular would still have a proportion of normal glomeruli in the biopsy,22 and variation in the glomerular lesion also in relation to chronic lesions such as fibrous crescents and global glomerulosclerosis was encountered. In this study, dialysis independency at presentation, presence of normal glomeruli and a relatively mild interstitial infiltrate were associated with a favourable outcome. A variant of anti-GBM disease, ‘double positive’ disease marked by presence of circulating ANCA, directed predominantly to MPO is present in 10%–50% of patients with anti-GBM. While the renal presentation of these patients is similar to isolated anti-GBM disease, patients with ‘double positive’ disease often have a relapsing disease course akin to ANCA vasculitis and require maintenance immunosuppression.
Unlike other diseases presenting with detectable antibodies (dsDNA in LN, ANCA in ANCA-GN), the titres of anti-GBM antibodies have a relevance in guiding immunosuppressive therapy. The ultimate therapeutic goal is reduction of circulating anti-GBM antibodies to a normal range or a range which is considered ‘non-toxic’,23 the latter depending on the specific assay used to detect antibodies.
In ANCA-associated vasculitis, kidney disease is most frequent in microscopic polyangiitis (>80%), while less frequent in granulomatosis with polyangiitis (around 60%) and in eosinophilic granulomatosis with polyangiitis (around 25%–30%). Kidney disease can present as slowly progressive24 over time or as a rapidly progressive glomerulonephritis, characterised by a rapid deterioration of kidney function.25
ANCA bind to peripheral neutrophil epitopes, which through a complex interaction between triggered neutrophils and the endothelium ensues in what we recognise as vasculitis.26 If this damage occurs in glomeruli, the inflammatory process destroys the capillary loops resulting in fibrinoid necrosis, and consequently, inflammatory mediators will leak into the Bowman’s space, resulting in proliferation of parietal epithelial cells eventually forming crescents (figure 2C). In ANCA-GN, however, antibodies succumb in the inflammation and only the bystander effect of complement activation is observed in some biopsies.
ANCA-GN is characterised by the virtual absence of deposits (‘pauci-immune’, figure 1E). However, by EM, studies showed that immune complex deposits were found in half of the patients and a majority (87% of 126 patients) showed positive IF findings for at least one immunoglobulin or complement component, even though staining was in general subdued.27 Patients with MPO-ANCA vasculitis and IgG deposits tend to have poorer kidney survival.28 In-depth analysis found a variable degree of complement deposition reflecting involvement of the alternative complement pathway, with a higher frequency in MPO-ANCA vasculitis compared with PR3-ANCA vasculitis.29 30 Glomerular C3d staining not only associated with severity of kidney function impairment and lower response rates to therapy,31 but also formation of cellular crescents.29
Numerous other glomerulonephritides can be encountered by the nephrologist and are summarised according to the presence of immune deposits/complexes in figure 5. Many of these, however, fall outside the realm of the rheumatologist.
Circulating immune complexes and location of immune deposits/complexes within glomerular structures
Once there are circulating immune complexes (CIC), it is likely that they will deposit in the kidney, and this process has been linked to disease pathogenesis in several autoimmune disorders. In SLE, the amount of CIC correlates with disease activity and kidney involvement, and changes of CIC levels predict therapy response.32 In most cases with cryoglobulinaemia (especially types II and III), the cryoglobulins have rheumatoid factor activity, that in turn enables them to form immune complexes.33 In IgAV, IgA1-containing CICs are usually detected, which are larger in size compared with those detected in IgAN.34 ANCA-associated vasculitis is considered an antibody-mediated disorder, and it remains obscure if there is a role of CICs, which has recently been reported in a small study from Japan.35 Irrespective of the nature of the deposits, their location is closely associated with clinical symptoms, as depicted in figure 4. Mesangial deposits will lead to hypercellularity of mesangial fields and broadening of the mesangial matrix. This is clinically associated with haematuria: through expansion of mesangial areas, breaks in the basement membrane will ensue leading to loss of erythrocytes in Bowman’s space. Subepithelial deposits will eventually lead to spike formation: rearrangement of the basement membrane around the deposits that look similar to spikes in a silver staining. Only subendothelial deposits will elicit an inflammatory response that co-occurs with complement activation, by which inflammatory cells such as neutrophils will be attracted that will try to get rid of the deposits, but in the process, will destroy parts of the basement membrane through release of inflammatory enzymes. Because subepithelial deposits, and to some extent mesangial deposits are further removed from the immune system they will elicit a less severe inflammatory response than subendothelial deposits.
For this review, we have focused on five renal diseases which are under the ‘shared care’ of rheumatologists and nephrologists to show the many facets of ICGN and how they relate to our insights into the pathogenesis of disease, diagnosis and treatment. A selection of different glomerular lesions is given in figure 2A–F.
How do immune complexes/cells damage the kidney?
The filtration barrier comprised of endothelium, GBM and podocytes which are the main target of inflammatory and non-inflammatory injury in glomerular disease. Most exogenous non-renal antigens collect in the subendothelial space and mesangial areas that are close to the circulation allowing antibody binding, production of anaphylatoxins and recruitment of inflammatory cells.36 The complement system, neutrophil/macrophage stimulation and the induction of several cytokines/chemokines lead to tissue inflammation, and thus damage of kidney structures.37 Additionally, mesangial cells and endothelial cells are activated by complement and deposition of membrane attack complex results in mesangial expansion, endothelial cell detachment and apoptosis.38 ICGNs are histologically characterised by distinct patterns of deposition of immune deposits mostly accompanied by complement deposits, especially C3 and C1q. Immune deposits usually precede the appearance of histological evidence for glomerular lesions.6
Among the many factors contributing to autoimmunity, neutrophil extracellular traps (NETs) have a prominent role in ICGN. NETs contain neutrophilic granules, histones and decondensed chromatin which also contain autoantigens. NETosis, a process by which chromatin is released, uncovers enzymes and autoantigens to the extracellular circulation in an inflammatory context (figure 6). Blood of patients with LN and AAV demonstrate increased numbers of unique low-density granulocytes which have high NET-generating capacity and also display impaired NET degradation due to the presence of DNase1 inhibitors or anti-NET antibodies. NETs colocalise with immune deposits and a failure to degrade NETs, either due to presence of DNase1 inhibitors or anti-NET antibodies, promotes development of LN.7 At present, it is unclear if NETosis directly contributes to disease pathogenesis or if it is a ‘bystander’ reaction of the inflammatory response.39 Therapeutic trials with agents such as CIT-01340 to inhibit NET formation and promote NET clearance will help to clarify the role of NETs in autoimmunity.
Further important steps take place during the natural course of ICGN, leading to progression of kidney lesions. A decrease in Dnase1 gene transcription and an accumulation of activated caspase 3-positive cells in kidney coincides with transition from a mesangial to a membranoproliferative pattern of LN indicative of disease progression.41 42 Among other factors, megsin, a serine protease inhibitor, is involved in mesangial matrix expansion. The increase of mesangial cells was also linked to an augmented deposition of immune complexes, immunoglobulins and complement components, as highlighted by the presence of electron-dense deposits in transgenic mice as early as at 20 weeks. A potential explanation for this role of megsin is the inhibitory effect of megsin on plasmin activity. The plasminogen activator/plasmin cascade plays an important role in degrading matrix components, and this might be disturbed by the presence of megsin–plasmin complexes.43
The evolvement of crescent formation in the context of MPGN requires alterations of the complement system, as only double-knockout factor H mice developed crescents.44 Complement alternative pathway anaphylatoxin C5a plays an essential role in neutrophil influx in a cryoglobulin-induced glomerulonephritis model and has shown a crucial involvement in the pathogenesis of several autoimmune diseases including AAV.45 46 The absence of C5 in an ICGN model resulted in reduced crescent formation and deposition of immune complexes.47 The complement system plays a pivotal role in perpetuating inflammatory responses. In C3-deficient mice a pronounced accumulation of immune complexes and a progressive decline in kidney function was reported after injection of anti-GBM antibodies.48 Lower C3 levels in circulation of patients with AAV are associated not only with reduced patient and kidney survival, but also indicates a proportion of patients at risk to develop CKD.49 50 Additionally, C3 deposits in the kidney are associated with worse renal and patient survival.51
Importantly, the presence of immune complexes in glomeruli alone is not sufficient to induce severe nephritis in a LN mouse model.52 Rather, there is a delicate interplay between inflammatory immune responses and inhibitory pathways, but once an imbalance in favour of inflammation occurs, kidney injury evolves. In addition, tissue damage caused by immune complexes is dependent on the biochemical and biologic properties of the antigen and antibody and the relative concentration of the antigen and antibody in the circulation and tissues. Thus, the sole presence of immune deposits/complexes might not be capable to induce related tissue lesions, but rather the concomitant induction of inflammatory pathways involving the innate and adaptive immune system leads to tissue injury.
Presence of immune deposits/complexes and prognostication/therapeutic response
The presence, location and type of immune deposits in the kidney is directly associated with the pattern and severity of glomerular injury and with clinical features and outcome. In LN, membranous or class V LN has better prognosis compared with the class III and IV despite more severe proteinuria,53 while in IgAV, the deposition of the terminal complement complex colocalised with IgA is associated with decreased kidney function and nephrotic syndrome,54 which resulted in a significant increase in prescription of immunosuppression in this cohort.
Nephritogenicity in anti-GBM disease is characterised by production of pathogenic antibodies against constituents of the basement membrane, comprising the non-collagenous domain of α3 chain of type IV collagen. Alongside linear IgG deposition on GBM, patients with anti-GBM typically present with cellular crescents present in most glomeruli, which directly predicts overall renal survival.23 Our understanding of kidney histology change over time is limited to ‘atypical’ anti-GBM disease, but a transition from acute lesions to chronic damage (presence of global glomerulosclerosis) needs to be expected in cases with severe kidney disease.
The inflammatory response seen in many diseases with immune deposits will eventually lead to chronic lesions with global glomerulosclerosis and interstitial fibrosis (IF) as characteristic features of common final pathways of kidney damage, if the respective processes are not terminated early.26 55 Repeat kidney biopsy (either protocol biopsies or as per indication) indicated that the number of globally sclerosed glomeruli and the proportion of patients with severe IF/tubular atrophy (IF/TA) increased in ANCA-GN with evidence of active disease despite immunosuppressive treatment.56 This indicates that despite treatment and clinical remission, sub-clinical inflammation and disease progression may still progress unnoticed. In line, protocol biopsies in LN indicate an increase of the Chronicity Index (CI), IF/TA and glomerulosclerosis over time. Higher percentage of glomerulosclerosis and IF/TA, and higher CI are associated with CKD progression.57 A possible explanation, especially in patients that lack response to therapy, is that persistent glomerular overexpression of interferon and JAK/STAT signalling is found in transcriptome analyses in non-responding patients in comparison to those achieving remission.58 Single cell RNA sequencing revealed local activation of B cells, an interferon response of most cells, and a crucial role of chemokine receptors in LN. More importantly, these transcripts in urine and kidney correlated with each other and reflect immunological activity contributing to kidney involvement.59 This would allow to reduce the number of kidney biopsies, which is not well accepted by most patients. A further step towards prediction of kidney disease and specific lesions is a machine learning approach. Combination of RNA sequencing with demographic and laboratory parameters had an accuracy of 81.7% to predict active LN as compared with patients without LN, and this model was influenced by dsDNA titers, age, male sex and the expression of the PTPRO and IL10RA genes.60 Disease flares of LN could be predicted by six variables, including partial remission, presence of endocapillary hypercellularity (at baseline biopsy), age, serum albumin, dsDNA and serum complement C3,61 thus machine learning approaches might also displace the need for repeated kidney biopsies in LN.
Treatment approaches of immune-mediated diseases should aim to immediately abrogate the transition to irreversible damage. Uncertainty, however, exists if resolution of immune deposits on initiation of immunosuppression plays a role in this context. In repeated kidney biopsies of patients with membranous LN, the resorption of immune deposits was seen more frequently in patients treated with rituximab compared with conventional immunosuppression, and this was associated with a favourable treatment response.62 The utility of repeat kidney biopsies to evaluate the role of persistent immune deposits together with the histological alterations in particular in relation to chronicity, clearly warrants further study. Novel methods may allow prediction of progression of specific lesions, and will incorporate multiple ‘omics’ approaches and machine learning algorithms.
New therapeutic avenues
Newer substances specifically tackling inflammatory pathways are needed to mitigate the transition of acute changes to chronic damage seen on repeat kidney biopsies.
Imlifidase (IdeS, IgG-degrading enzyme of Streptococcus pyogenes) is capable to cleave IgG from circulation within minutes63 and thus is a therapeutic option for IgG antibody-mediated diseases, such as anti-GBM disease, renal transplantation, but also Guillain-Barre syndrome. Imlifidase was tested in a mouse model of anti-GBM disease. Kidney-bound IgG was cleaved by IdeS by approximately 93.4%, and this also reduced the glomerular influx of leukocytes by 62% and the staining of C3 and C1q.64 A phase IIa trial in anti-GBM disease recruiting 15 patients with severely impaired kidney function found that 10 patients at 6 months were free of dialysis with a median GFR of 27 mL/min/1.73 m2.23 65 A phase III trial in anti-GBM disease is in the set-up phase. Some of the patients in the phase IIa trial were double-positive (anti-GBM and ANCA), and imlifidase led to a similar complete disappearance of ANCA after therapy. A single case report of a patient with severe respiratory compromise due to AAV was treated with imlifidase and weaned off venovenous extracorporeal membrane oxygenation after therapy.66 Further developments in antibody-mediated diseases might be expected.
Avacopan, which blocks the C5aR1, ameliorated the formation of crescents in a mouse model of MPO-ANCA vasculitis in a dose-dependent fashion. In addition, significant reductions of haematuria and proteinuria were reported.67 In the phase II trial CLEAR both avacopan groups had a more rapid decline in albuminuria and overall disease activity.68 The phase III trial ADVOCATE randomised 331 patients to either avacopan plus standard of care or prednisone plus standard of care. The composite primary endpoint of remission at week 26 and sustained remission at week 52 were reached by 72.3% versus 70.1% and 65.7% versus 54.9% participants in the avacopan and prednisone groups, respectively. Patients in the avacopan group had higher albuminuria values at baseline and a significant decrease of albuminuria by week 4, but there was no difference of albuminuria change between groups at week 52. A significant difference in change of eGFR between groups was observed at week 26 and week 52, with an increase of 7.3 mL/min/1.73 m2 in the avacopan and 4.1 mL/min/1.73 m2 in the prednisone arm at week 52, respectively.69 The C5aR1 not only primes neutrophils for activation by ANCA, it further perpetuates the generation of ANCA, but also leads to neutrophil retention and reactive oxygen species bursts within glomerular capillaries.70 The C5aR1 is expressed by other inflammatory cells with relevance in ANCA-GN, such as monocytes and macrophages.71 Information about histology and especially repeat biopsies, which was optional in the ADVOCATE trial, are not published thus far. Other complement inhibitors, such as iptacopan, an oral factor B inhibitor, are under investigation in several glomerular diseases, and it seems that targeting complement pathways will revolutionise management strategies in kidney diseases. However, it is unclear so far if these therapies also reduce immune deposits in kidney tissue.
In summary, immune deposits in the kidney are a key feature of manifestations of autoimmune kidney diseases. There is, however, still limited data to support their pathogenetic evidence, but in general the location, the density and the property of deposits predict clinical presentation and disease severity. Experimental therapies have not specifically been developed to tackle immune deposits. Ultimately, future research will need to involve protocol kidney biopsies, multi-omics approaches and artificial intelligence to assess time-dependent changes of immune deposits potentially indicating response to therapy.
Patient consent for publication
Handling editor David S Pisetsky
AK and IB contributed equally.
Correction notice This article has been corrected since it published Online First. The third author affiliation has been updated.
Contributors All four authors have contributed to the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests AK received consulting fees from Vifor Pharma, Otsuka, Alexion, UriSalt, Delta4 and Catalyst Biosciences. IB received consulting fees from Boehringer-Ingelheim, Novartis, Catalyst Biosciences and Toleranzia. DG received consulting fees from ChemoCentryx. MS received consulting fees from Astra Zeneca, Boehringer-Ingelheim, Novartis and Otsuka.
Provenance and peer review Not commissioned; externally peer reviewed.